Indo Us Biotech Share Price Today (INDOUS)
TODAY IN ONE LINE
INDOUS fell 2.2% on light volume, lagging Nifty's -0.4% move, hovering dangerously near its 52-week low.
With a market cap of ₹170.44 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Indo Us Biotech flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 15.4% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 16.9%
- ●High Promoter HoldingPromoters hold 68.3% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 47.3% YoY
Latest Indo Us Biotech News
What changed recently?
Recent events, corporate actions, and announcements.
Indo Us Biotech Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Indo Us Biotech Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Indo Us Biotech Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Indo Us Biotech Limited — derived from the live tape, not yesterday's close.
Indo Us Biotech Limited last traded at ₹84.98 with an intraday range of ₹84.6–₹88.8 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹84.98| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 96.05 | +11.07 | +13.03% |
| R3 | 91.85 | +6.87 | +8.09% |
| R2 | 90.33 | +5.35 | +6.29% |
| R1 | 87.65 | +2.67 | +3.15% |
| PIVOT | 86.13 | 1.15 | 1.35% |
| CURRENT | 84.98 | — | — |
| S1 | 83.45 | -1.53 | -1.80% |
| S2 | 81.93 | -3.05 | -3.59% |
| S3 | 79.25 | -5.73 | -6.74% |
| S4 | 75.05 | -9.93 | -11.68% |
INDOUS is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹85.2–₹88.8
Trading Below opening range, showing Bearishness
Indo Us Biotech Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Indo Us Biotech Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Indo Us Biotech Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹170.44 Cr. and reported EPS of ₹6.54.
| Metric | Mar 2021 | Mar 2022 |
|---|---|---|
| Revenue from Operations | 40,11,033 | 50 ▼ 100.0% |
| Sales Growth YoY %Derived | — | -100.00% |
| Other Income | 4,299 | 0 ▼ 100.0% |
| Total Income | 40,15,331 | 50 ▼ 100.0% |
| 25,25,039 | 36 ▼ 100.0% | |
| Gross ProfitDerived | 14,85,993 | 14 ▼ 100.0% |
| Gross Margin %Derived | 37.05% | 27.76% |
| 9,53,418 | 7 ▼ 100.0% | |
| EBITDA (Operating Profit)Derived | 5,32,575 | 7 ▼ 100.0% |
| OPM %Derived | 13.28% | 13.51% |
| 1,43,972 | 2 ▼ 100.0% | |
| Profit Before Tax (PBT) | 3,92,902 | 5 ▼ 100.0% |
| -97,069 | 0 ▲ 100.0% | |
| Effective Tax %Derived | -24.71% | 4.67% |
| Total Profit for Period | 4,89,971 | 5 ▼ 100.0% |
| Net Profit (Owner's PAT)Derived | 4,89,971 | 5 ▼ 100.0% |
| Net Profit Margin %Derived | 12.22% | 10.11% |
| PAT Growth YoY %Derived | — | -100.00% |
| Earnings Per Share (EPS ₹) | 3,36,445.46 | 3.48 ▼ 100.0% |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 36,22,429 | 45 ▼ 100.0% |
| Material Cost % of RevenueDerived | 62.61% | 4.35% |
| Employee Cost % of RevenueDerived | 1.28% | 1.42% |
| Other Cost % of RevenueDerived | 22.49% | 12.82% |
| Interest Coverage (x)Derived | 4.33x | 5.36x |
| Period | Mar 2021 | Mar 2022 | Trend |
|---|---|---|---|
| Revenue from Operations | 40,11,033 | 50 ▼ 100.0% | |
| Sales Growth YoY %Derived | — | -100.00% | |
| Other Income | 4,299 | 0 ▼ 100.0% | |
| Total Income | 40,15,331 | 50 ▼ 100.0% | |
25,25,039 | 36 ▼ 100.0% | ||
| Gross ProfitDerived | 14,85,993 | 14 ▼ 100.0% | |
| Gross Margin %Derived | 37.05% | 27.76% | |
9,53,418 | 7 ▼ 100.0% | ||
| EBITDA (Operating Profit)Derived | 5,32,575 | 7 ▼ 100.0% | |
| OPM %Derived | 13.28% | 13.51% | |
1,43,972 | 2 ▼ 100.0% | ||
| Profit Before Tax (PBT) | 3,92,902 | 5 ▼ 100.0% | |
-97,069 | 0 ▲ 100.0% | ||
| Effective Tax %Derived | -24.71% | 4.67% | |
| Total Profit for Period | 4,89,971 | 5 ▼ 100.0% | |
| Net Profit (Owner's PAT)Derived | 4,89,971 | 5 ▼ 100.0% | |
| Net Profit Margin %Derived | 12.22% | 10.11% | |
| PAT Growth YoY %Derived | — | -100.00% | |
| Earnings Per Share (EPS ₹) | 3,36,445.46 | 3.48 ▼ 100.0% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 36,22,429 | 45 ▼ 100.0% | |
| Material Cost % of RevenueDerived | 62.61% | 4.35% | |
| Employee Cost % of RevenueDerived | 1.28% | 1.42% | |
| Other Cost % of RevenueDerived | 22.49% | 12.82% | |
| Interest Coverage (x)Derived | 4.33x | 5.36x |
Indo Us Biotech segment analysis : revenue and profit mix.
Disclosed business segments at Indo Us Biotech with their share of revenue and profit, switchable between consolidated and standalone reporting.
Indo Us Biotech discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Indo Us Biotech Limited.
Our AI distills the core fundamental drivers supporting Indo Us Biotech Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Indo Us Biotech Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 14.59% substantially exceeds peer average 10.56% by 403 basis points.
Net margin 11.88% beats peer median 7.97%, demonstrating superior profitability efficiency.
ROE 16.90% and ROCE 15.40% surpass sector averages, indicating strong capital deployment.
Promoter holding 68.29% ensures stable long-term governance and founder alignment.
Quarterly sales growth 5.64% YoY shows resilience despite broader revenue headwinds.
Key Risks.
Latest quarterly EPS declined 46.5% YoY, signaling severe earnings compression.
TTM EPS declined 47.3% YoY, highlighting persistent profitability deterioration.
Negative operating cash flow ₹16.09 Cr in FY26 undermines liquidity and sustainability.
P/E 55.40x indicates potential overvaluation relative to current earnings power.
Zero institutional ownership limits market liquidity and external investor validation.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 12% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.14%.
Indo Us Biotech Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Indo Us Biotech Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Indo Us Biotech Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Indo Us Biotech Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Indo Us Biotech Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Indo Us Biotech Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Indo Us Biotech Limited stood at 49.0% of traded volume, against a 20-day average of 69.1%.
Indo Us Biotech announcements: results, concalls, ratings, M&A.
Filings Indo Us Biotech sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Indo Us Biotech files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 66 documents below.
General Updates
Indo Us Biotech Limited has informed the Exchange about Revised Outcome of the Board Meeting held on 10 July 2026. Reconstitution of…
General Updates
Indo Us Biotech Limited has informed the Exchange about Revised: Additional Details Required For Corporate Announcement Filed Under Regulation 30 Of…
Outcome of Board Meeting
Indo Us Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on July 10, 2026 Change in Composition of Committees of the…
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Indo Us Biotech Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
Disclosure under SEBI Takeover Regulations
Jagdishkumar Devjibhai Ajudiya has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of…
Indo Us Biotech dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Indo Us Biotech has declared, sequenced by announce and record date.
Indo Us Biotech corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Indo Us Biotech insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Indo Us Biotech as reported to SEBI — buying and selling signals from the people who know the business best.
Indo Us Biotech insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| INDO US AGRISEEDS LIMITED | Insider | 02 Mar 2026 | buy | +50.0 K | ₹70.5 L | ₹141.00 |
About Indo Us Biotech Limited: business, sector, key facts.
What Indo Us Biotech Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Indo Us Biotech Limited operates in the Other Agricultural Products industry under the Fast Moving Consumer Goods sector, listed as NSE: INDOUS, BSE: 541304.
Indous Bio-Tech Limited is an Indian company specializing in the agricultural sector, primarily focused on the production, processing, packaging, and marketing of a wide variety of seeds. Their product portfolio encompasses a broad spectrum of agricultural needs, catering to both commercial and vegetable seed requirements.
Their vegetable seed offerings are extensive, including popular choices like tomatoes, okra, and various gourds, alongside root vegetables, leafy greens, and peppers. Beyond vegetables, they also supply cotton seeds and a significant range of oil seeds, such as castor, groundnut, sesame, mustard, and soyabean. The company's product line extends to spices, including cumin and isabgul, pulses (like gram and black gram), and cereals such as wheat and maize.
A key aspect of Indo Us Bio-Tech's business model involves providing agricultural education to local farmers. This commitment to supporting the farming community likely contributes to both the company's success and the broader agricultural development within India. This educational support could involve best practices, modern techniques, or even seed-specific growing advice.
The company's reach extends beyond the domestic market, with a notable export presence in several countries. Their international clientele includes destinations in North America (USA), the Middle East (Kuwait), and various locations in Africa and Asia (Cameroon, Sri Lanka, Mauritius). This demonstrates a capacity for international trade and a successful approach to competing in global agricultural markets. Their export success suggests a high-quality product and efficient operations.
Established in 2004 and headquartered in Ahmedabad, India, Indo Us Bio-Tech Limited has built a substantial presence in the Indian seed industry, leveraging a diverse product portfolio, commitment to farmer education, and successful international expansion.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Ajooni Biotech (AJOONI) Share PricePeer
- Amir Chand Jagdish Kumar (Exports) (AMIRCHAND) Share PricePeer
- B & A (BNALTD) Share PricePeer
- Bombay Super Hybrid Seeds (BSHSL) Share PricePeer
- Comfort Intech (COMFINTE) Share PricePeer
- Stocks near 52-week low (reversal watch)Screener
- Reversal Hunter strategy playbookStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about Indo Us Biotech Limited (INDOUS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Indo Us Biotech Limited (INDOUS)?
The current share price of Indo Us Biotech Limited (INDOUS) is ₹84.98. Today, the stock has declined by ₹1.95 (2.24%), trading in a range of ₹84.6 to ₹88.8. The stock opened at ₹88.69 with a trading volume of 17,311 shares.
02Is Indo Us Biotech Limited stock a good investment for long-term?
Indo Us Biotech Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹170.44 crores, P/E ratio of 0.00, ROE of 16.90%, and ROCE of 15.40%. The dividend yield stands at 0.29%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Indo Us Biotech Limited stock?
The 52-week high price of Indo Us Biotech Limited (INDOUS) is ₹182.1, while the 52-week low is ₹84.91. Currently trading at ₹84.98, the stock is 0.1% away from its 52-week low and 53.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Indo Us Biotech Limited stock at the current price?
Whether to buy Indo Us Biotech Limited stock at ₹84.98 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 0.00. Today's performance shows a loss of 2.24%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Indo Us Biotech Limited and when is the next dividend?
Indo Us Biotech Limited offers a dividend yield of 0.29%, which means for every ₹100 invested at the current price of ₹84.98, you can expect to receive approximately ₹0.29 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Indo Us Biotech Limited?
Indo Us Biotech Limited's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: 0.00, ROE: 16.90%, ROCE: 15.40%, Dividend Yield: 0.29%, EPS: ₹6.54, Book Value: ₹45.99, and Debt-to-Equity: 0.33. The company's market cap stands at ₹170.44 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Indo Us Biotech Limited stock performing today in the market?
Indo Us Biotech Limited stock opened at ₹88.69 and is currently trading at ₹84.98, showing a decline of ₹1.95 (2.24%). The intraday high is ₹88.8 and low is ₹84.6. The trading volume stands at 17,311 shares, indicating moderate market participation today.
08What is the P/E ratio of Indo Us Biotech Limited and what does it indicate?
Indo Us Biotech Limited has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹6.54, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Indo Us Biotech Limited (INDOUS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.